The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
 
Edoardo Francini
Honoraria - Janssen-Cilag
Research Funding - Roche
Travel, Accommodations, Expenses - Janssen-Cilag
 
Francesco Montagnani
No Relationships to Disclose
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Miguel Gonzalez-Velez
No Relationships to Disclose
 
Nimira S. Alimohamed
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen; Merck; Pfizer; Sanofi
 
Antonio Cigliola
No Relationships to Disclose
 
Irene Moreno
Honoraria - BMSi
 
Jaime Rubio
No Relationships to Disclose
 
Francesca Crivelli
No Relationships to Disclose
 
Grace Shaw
No Relationships to Disclose
 
Roberto Petrioli
No Relationships to Disclose
 
Carmelo Bengala
No Relationships to Disclose
 
Guido Francini
Research Funding - Roche (I)
Travel, Accommodations, Expenses - Janssen-Cilag (I); Sanofi (I)
 
Jesus Garcia Foncillas
Consulting or Advisory Role - Bayer; Merck
Travel, Accommodations, Expenses - Janssen; Roche
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Celestia S. Higano
Honoraria - Astellas Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen Oncology; Pfizer
 
Alan Haruo Bryce
Honoraria - Astellas Pharma
Travel, Accommodations, Expenses - Clovis Oncology
 
Lauren Christine Harshman
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech; Jounce Therapeutics; Merck; Michael J. Hennessy Associates; Novartis; Ology Medical Education; Pfizer; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Endocyte (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Genentech
 
Richard Lee-Ying
Honoraria - Janssen
Consulting or Advisory Role - Bayer; Janssen
Research Funding - Sanofi
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)